Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

Obesity

Treatments

Other: Placebo
Drug: Liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT03041792
A9001498

Details and patient eligibility

About

This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.

Enrollment

61 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and female subjects;
  • Body Mass Index 30-40 kg/m2;

Exclusion criteria

Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

Trial design

61 participants in 2 patient groups, including a placebo group

Active
Experimental group
Description:
Liraglutide
Treatment:
Drug: Liraglutide
Placebo
Placebo Comparator group
Description:
Placebo comparator
Treatment:
Other: Placebo

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems